Marie Bretagne

Marie Bretagne

Auto-generated profile, based on publicly available information

Marie Bretagne

Departments of Pharmacology (N.J., M.B., M.R., B.A., J.-E.S.), AP-HP

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JSJoe-Elie Salem
Joe-Elie Salem
MBMarie Bretagne
Marie Bretagne
BABaptiste Abbar
Baptiste Abbar
SLSarah Leonard-Louis
Sarah Leonard-Louis
SEStéphane Ederhy
Stéphane Ederhy
YAYves Allenbach
Yves Allenbach
Immune-checkpoint-inhibitor (ICI)–associated myotoxicity involves the heart (myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are highly fatal. We report the results of a strategy that included identification of individuals with severe ICI myocarditis by also screening for and managing concomitant respiratory muscle involvement with mechanical ventilation, as well as treatment with the CTLA4 fusion protein abatacept and the JAK inhibitor ruxolitinib. Forty cases with definite ICI myocarditis were included with pathologic confirmation of concomitant myositis in the majority of patients. In the first 10 patients, using recommended guidelines, myotoxicity-related fatality occurred in 60%, consistent with historical controls. In the subsequent 30 cases, we instituted systematic screening for respiratory muscle involvement coupled with active ventilation and treatment using ruxolitinib and abatacept. The abatacept dose was adjusted using CD86 receptor occupancy on circulating monocytes. The myotoxicity-related fatality rate was 3.4% (1/30) in these 30 patients versus 60% in the first quartile (P < 0.0001). These clinical results are hypothesis-generating and need further evaluation. Significance: Early management of respiratory muscle failure using mechanical ventilation and high-dose abatacept with CD86 receptor occupancy monitoring combined with ruxolitinib may be promising to mitigate high fatality rates in severe ICI myocarditis. See related commentary by Dougan, p. 1040. This article is highlighted in the In This Issue feature, p. 1027

7 April 2026 in Circulation
Verified
Journal Article
Closed access
NJNaim Jebnoun
Naim Jebnoun
MBMarie Bretagne
Marie Bretagne
MRMichelle Rosenzwajg
Michelle Rosenzwajg
YAYves Allenbach
Yves Allenbach
BABaptiste Abbar
Baptiste Abbar
JSJoe-Elie Salem
Joe-Elie Salem

4 May 2023
Verified
Other
Open access
PDF file
JSJoe-Elie Salem
Joe-Elie Salem
MBMarie Bretagne
Marie Bretagne
BABaptiste Abbar
Baptiste Abbar
SLSarah Leonard-Louis
Sarah Leonard-Louis
SEStéphane Ederhy
Stéphane Ederhy
YAYves Allenbach
Yves Allenbach
Definitions used for adjudication and grading of the different evaluated events

21 April 2023
Verified
Other
Open access
PDF file
JSJoe-Elie Salem
Joe-Elie Salem
MBMarie Bretagne
Marie Bretagne
BABaptiste Abbar
Baptiste Abbar
SLSarah Leonard-Louis
Sarah Leonard-Louis
SEStéphane Ederhy
Stéphane Ederhy
YAYves Allenbach
Yves Allenbach
Diagnostic work-up for suspected ICI-myocarditis and evaluation of severity criteria

21 April 2023
Verified
Other
Open access
JSJoe-Elie Salem
Joe-Elie Salem
MBMarie Bretagne
Marie Bretagne
BABaptiste Abbar
Baptiste Abbar
SLSarah Leonard-Louis
Sarah Leonard-Louis
SEStéphane Ederhy
Stéphane Ederhy
YAYves Allenbach
Yves Allenbach
Example of the first severe ICI-myocarditis case treated with abatacept guided by real-time immune-monitoring assessment of CD86RO (CD86 receptor occupancy) on circulating monocytes.

4 May 2023
Verified
Other
Open access
JSJoe-Elie Salem
Joe-Elie Salem
MBMarie Bretagne
Marie Bretagne
BABaptiste Abbar
Baptiste Abbar
SLSarah Leonard-Louis
Sarah Leonard-Louis
SEStéphane Ederhy
Stéphane Ederhy
YAYves Allenbach
Yves Allenbach
Effect of plasmapheresis on ICI circulating levels in the 10 patients receiving plasmapheresis in our cohort.